Hansard

The next question is, that motion S5M-12856, in the name of Anas Sarwar, on access to vital medicines, as amended, be agreed to.

Motion, as amended, agreed to,

That the Parliament calls on the Scottish Government, as a matter of urgency, to bring NHS National Services Scotland, the Scottish Medicines Consortium and the relevant pharmaceutical companies together to deliver access to the life-prolonging medicines, Perjeta and Orkambi, for patients in Scotland who need them; notes the commitment that was made by the Scottish Government in December 2016, following the Review of Access to New Medicines (the Montgomery Review), to improve ways of negotiating with drug companies on the cost of medicines; calls for a new system of negotiation to be implemented now; welcomes the introduction of a new ultra-orphan pathway within the Scottish Medicines Consortium process that will make available, with ongoing evaluation for at least three years, medicines for the rarest conditions; notes the roll-out of the Peer Approved Clinical System in June 2018, replacing individual patient treatment requests, which allows clinicians to seek medicines for their patients that are not currently accepted for routine use by the NHS in Scotland, and which makes clear that the cost of the medicine must not be part of the decision-making process; further notes the commitment of the Scottish Government to continue to use all Pharmaceutical Price Regulation Scheme rebate funding to support access to new medicines; welcomes the commitment of the Association of the British Pharmaceutical Industry for its members to provide Scotland with the same discounts offered elsewhere in the UK for accessing medicines; believes that pharmaceutical companies should offer NHS Scotland fair prices and should properly engage with health technology assessments in order to demonstrate the clinical effectiveness of their medicines, and further calls on the Scottish Government to remove barriers to make access to new drugs easier, including the reform of the Patient Access Scheme Assessment Group.